Uncategorized
Obesity could be treated without suppressing appetite

Obesity could be treated in other ways than using drugs suppressing appetite, a study reveals.
Researchers identified how brown fat cells, which are linked to weight loss, communicate to expand nerve and blood vessel networks, boosting heat generation. The findings, published in Nature Communications, hint at new ways to treat obesity beyond approaches focusing on suppressing appetite.
Most of the fat in human bodies is white fat, which stores excess energy, but leads to obesity at too high levels. Brown fat is a specialised tissue that regulates body temperature and is closely linked to weight loss and metabolic health, but humans and other mammals have smaller amounts.
When brown fat is activated by exposure to cold, it uses the body’s resources including glucose and lipids to generate heat, a process called thermogenesis. While research on brown fat has largely focused on stimulating fat cells to generate heat, less is known about how these underlying networks function, which could help treat obesity.
“During thermogenesis, all of that chemical energy is dissipated as heat instead of being stored in the body as white fat,” said Farnaz Shamsi, Assistant Professor of Molecular Pathobiology at NYU College of Dentistry and the study’s senior author.
“By rapidly taking up and using fuel sources from our bodies and the food that we eat, brown fat acts like a metabolic sink that draws in nutrients and prevents them from being stored.”
Findings ‘could be relevant in human obesity’
In the study, researchers used single-cell RNA sequencing to identify SLIT3, a protein secreted by brown fat cells, which was thought to play a role in how fat cells communicate.
When produced, SLIT3 gets cleaved into two different fragments. Using a combination of approaches in human and mouse cells, the researchers discovered the enzyme BMP1 cleaves SLIT3 into two. They determined that the two SLIT3 fragments control different processes: one grows the network of blood vessels, while the other expands the network of nerves.
Researchers also identified the receptor, PLXNA1, that binds to one of the SLIT3 fragments to control brown fat’s network of nerves. In studies in mice — which typically have very active brown fat and can tolerate cold temperatures for long periods of time — removing SLIT3 or the PLXNA1 receptor from brown fat resulted in mice becoming sensitive to cold and having difficulty maintaining their body temperatures.
To see if the findings translated to humans, researchers examined samples of fat tissue from more than 1,5000 people, some of whom had obesity. Focusing on the gene that produces SLIT3, which prior studies show is associated with obesity and insulin resistance, they found that SLIT3 gene expression may regulate fat tissue health, inflammation, and insulin sensitivity in people with obesity.
Most weight loss drugs, including GLP-1s, work to suppress appetite, decreasing the amount of food people eat and therefore the amount of energy stored. However, processes involved in brown fat could be harnessed for their therapeutic potential.
“That really got our attention, as it suggests that this pathway could be relevant in human obesity and metabolic health,” Shamsi added.
The post Obesity could be treated without suppressing appetite appeared first on Drug Discovery World (DDW).
Uncategorized
Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist Tubulis
The acquisition of Tubulis GmbH—Gilead Sciences’ latest of the year after buying Arcells and Ouro Medicines—brings into the fold a novel ovarian cancer candidate that has demonstrated promising mid-stage data.
Uncategorized
STAT+: Pharmalittle: We’re reading about FDA backing domestic production, another Gilead deal, and more
Rise and shine, everyone, another busy day is on the way. And it is getting off to a good start here on the Pharmalot campus, where clear blue skies and comfortable breezes are greeting us. Who could ask for anything more? Actually, we could — it is time to reheat the kettle for another cuppa stimulation. Our choice today is ginger peach. And here is a helpful tip — a teaspoon of honey enhances the flavors splendidly. Of course, you are invited to join us. For the full experience, we are now hawking replicas — take a look. Meanwhile, here are a few tidbits to help you along. As always, do keep in touch. We appreciate feedback, criticism, and tips. …
The U.S. Food and Drug Administration used the president’s budget to propose policies aimed at encouraging domestic development and manufacturing of drugs, STAT notes. FDA Commissioner Marty Makary has said the agency needs “giant, big ideas” to counter China’s dominance in early-stage clinical development of drugs. Among the FDA’s ideas are proposals to make it easier to run early-stage trials in the U.S. and to hand an advantage to U.S.-based generics manufacturers. The Trump administration has been using a variety of policy levers to try and bring drug manufacturing to the U.S. One of the legislative proposals in the FDA’s budget justification would let domestic manufacturers of generic drugs challenge brand drug patents a month before foreign companies, a major advantage in an intensely competitive process.
Two more drugmakers, AbbVie and Genentech, will officially start selling their medicines on the TrumpRx website, CBS News tells us. Abbvie, which struck a deal with the Trump administration in January to cut the cost of certain medicines, will sell Humira, a popular medication used to treat rheumatoid arthritis, Crohn’s disease, and ulcerative colitis, on the site at an 86% discount. The prescription prices on the site, however, are only available to patients who are uninsured, or whose insurance does not cover it, and who must pay the full list price out of pocket. Those with insurance coverage generally pay lower prices already. TrumpRx now sells over 61 drugs at a lower price, up from about 40 when the website went live in February.
Rise and shine, everyone, another busy day is on the way. And it is getting off to a good start here on the Pharmalot campus, where clear blue skies and comfortable breezes are greeting us. Who could ask for anything more? Actually, we could — it is time to reheat the kettle for another cuppa stimulation. Our choice today is ginger peach. And here is a helpful tip — a teaspoon of honey enhances the flavors splendidly. Of course, you are invited to join us. For the full experience, we are now hawking replicas — take a look. Meanwhile, here are a few tidbits to help you along. As always, do keep in touch. We appreciate feedback, criticism, and tips. …
The U.S. Food and Drug Administration used the president’s budget to propose policies aimed at encouraging domestic development and manufacturing of drugs, STAT notes. FDA Commissioner Marty Makary has said the agency needs “giant, big ideas” to counter China’s dominance in early-stage clinical development of drugs. Among the FDA’s ideas are proposals to make it easier to run early-stage trials in the U.S. and to hand an advantage to U.S.-based generics manufacturers. The Trump administration has been using a variety of policy levers to try and bring drug manufacturing to the U.S. One of the legislative proposals in the FDA’s budget justification would let domestic manufacturers of generic drugs challenge brand drug patents a month before foreign companies, a major advantage in an intensely competitive process.
Two more drugmakers, AbbVie and Genentech, will officially start selling their medicines on the TrumpRx website, CBS News tells us. Abbvie, which struck a deal with the Trump administration in January to cut the cost of certain medicines, will sell Humira, a popular medication used to treat rheumatoid arthritis, Crohn’s disease, and ulcerative colitis, on the site at an 86% discount. The prescription prices on the site, however, are only available to patients who are uninsured, or whose insurance does not cover it, and who must pay the full list price out of pocket. Those with insurance coverage generally pay lower prices already. TrumpRx now sells over 61 drugs at a lower price, up from about 40 when the website went live in February.
Uncategorized
FDA Seeks Expanded Authority To Regulate Postapproval Manufacturing Changes
FDA Seeks Expanded Authority To Regulate Postapproval Manufacturing Changes
Aiming to protect patients, the FDA sent lawmakers a wish list of legislative proposals intended to clarify and expand its oversight of updates to approved drug production processes. Read More
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Contributors9 years agoThe final 6 ‘Game of Thrones’ episodes might feel like a full season
-
Uncategorized9 years agoAccording to Dior Couture, this taboo fashion accessory is back
-
Uncategorized9 years agoThe old and New Edition cast comes together to perform
-
Uncategorized9 years agoPhillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years agoUber and Lyft are finally available in all of New York State
-
Uncategorized9 years agoDisney’s live-action Aladdin finally finds its stars
-
Uncategorized9 years agoSteph Curry finally got the contract he deserves from the Warriors